The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist Therapy. [PDF]
Biomedicines, 2022 Background: Dual Amylin and Calcitonin Receptor Agonists (DACRAs) are treatment candidates for obesity and type 2 diabetes. Recently, a once-weekly DACRA (KBP-A) showed promise, potentially due to its different exposure profile compared to daily DACRA ...
Sonne N +3 more
europepmc +4 more sources
Monash DaCRA fPET-fMRI: A dataset for comparison of radiotracer administration for high temporal resolution functional FDG-PET. [PDF]
Gigascience, 2022 Abstract Background “Functional” [18F]-fluorodeoxyglucose positron emission tomography (FDG-fPET) is a new approach for measuring glucose uptake in the human brain. The goal of FDG-fPET is to maintain a constant plasma supply of radioactive FDG in order to track, with high temporal resolution ...
Jamadar SD +7 more
europepmc +6 more sources
The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection - a novel disease-modifying osteoarthritis drug. [PDF]
Arthritis Res TherBackground Despite the extensive research to provide a disease-modifying osteoarthritis drug (DMOAD), there is still no approved DMOAD. Dual amylin and calcitonin receptor agonists (DACRA) can provide metabolic benefits along with antinociceptive and ...
Mohamed KE +6 more
europepmc +3 more sources
Safety, tolerability and pharmacokinetic characterisation of DACRA KBP‐042 in healthy male subjects [PDF]
British Journal of Clinical Pharmacology, 2021 There is a need for anti-diabetic agents successfully targeting insulin sensitivity and treating obesity control at the same time. The aim of this first-in-human study was 1) to evaluate safety and tolerability; 2) to evaluate pharmacokinetics and 3) to assess indications of receptor engagement of single ascending doses of KBP-042, a Dual Amylin and ...
Kim Henriksen, Ingrid M C Kamerling
exaly +3 more sources
A selective role for receptor activity-modifying proteins in subchronic action of the amylin selective receptor agonist NN1213 compared with salmon calcitonin on body weight and food intake in male mice. [PDF]
Eur J Neurosci, 2021 AMY3 mediates the effect of the dual amylin receptor agonist NN1213. Subchronic sCT does not reduce body weight in WT mice. Absence of AMY3 allows sCT to be active. Abstract The role of receptor activity‐modifying proteins (RAMPs) in modulating the pharmacological effects of an amylin receptor selective agonist (NN1213) or the dual amylin–calcitonin ...
Arrigoni S +6 more
europepmc +2 more sources
KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats. [PDF]
Mol Metab, 2021 Objective: Dual amylin and calcitonin receptor agonists (DACRAs) are novel therapeutic agents that not only improve insulin sensitivity but also work as an adjunct to established T2DM therapies.
Andreassen KV +5 more
europepmc +2 more sources
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases. [PDF]
Mol Metab, 2021 Background: Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and ...
Sonne N, Karsdal MA, Henriksen K.
europepmc +2 more sources
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. [PDF]
Front Endocrinol (Lausanne), 2020 The hormones amylin and calcitonin interact with receptors within the same family to exert their effects on the human organism. Calcitonin, derived from thyroid C cells, is known for its inhibitory effect on osteoclasts.
Mathiesen DS +4 more
europepmc +2 more sources
The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. [PDF]
BMC Endocr Disord, 2021 Background Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard.
Larsen AT +4 more
europepmc +2 more sources
Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity. [PDF]
J Diabetes InvestigSeveral ongoing trials are evaluating incretin‐based therapies, including GLP‐1 receptor agonists, for their effects on CKD and MASLD. These studies will offer insights into their potential for metabolic diseases in people with type 2 diabetes and obesity.
Bae JH, Cho YM.
europepmc +2 more sources